A measure of treatment response: Patient and physician satisfaction with traditional NSAIDs for osteoarthritis control

Open Access Rheumatology: Research and Reviews

Volumn 5, Issue , 2013, Pages 69-76

  Taylor, Stephanie D ^a   Everett, Sharlette V ^a   Taylor, Thomas N ^b   Watson, Douglas J ^a   Taylor Stokes, Gavin ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Cross sectional; Dissatisfaction; Pain; Survey

Indexed keywords

ACECLOFENAC; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ADULT; AGED; ARTICLE; CAUCASIAN; CROSS-SECTIONAL STUDY; DISEASE CONTROL; DRUG RESPONSE; FEMALE; GERMANY; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; OBESITY; OSTEOARTHRITIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PHYSICIAN SATISFACTION; QUESTIONNAIRE; SATISFACTION; SPAIN; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

EID: 84880932103     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: 10.2147/OARRR.S41940     Document Type: Article

References (15)

1. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008. Available from: http://www. who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed March 27, 2013.
2. National Institute for Health and Clinical Excellence. CG59 Osteoarthritis: The Care and Management of Osteoarthritis in Adults. London: Royal College of Physicians; 2008. Available from: http://www.nice.org.uk/nicemedia/live/11926/39720/39720.pdf. Accessed December 10, 2012.
3. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646-656.
4. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476-499.
5. Walker JS, Sheather-Reid RB, Carmody JJ, Vial JH, Day RO. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of responders and nonresponders. Arthritis Rheum. 1997;40(11):1944-1954.
6. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Realworld physician and patient behaviour across countries: DiseaseSpecific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063-3072.
7. EQ-5D [homepage on the Internet]. Rotterdam: EuroQol Group; 2002 [updated March 1, 2013]. Available from: http://www.euroqol.org/. Accessed December 10, 2012.
8. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-145.
9. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-1840.
10. Dworkin RH, Jensen MP, Gould E, et al. Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. J Pain. 2011;12(4): 416-424.
11. Lin HY, Cheng TT, Wang JH, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13(2):144-150.
12. Ramos-Remus CR, Hunsche E, Mavros P, Querol J, Suarez R. Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico. Curr Med Res Opin. 2004;20(5):691-698.
13. Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf. 2001;10(6):517-524.
14. Rahme E, Toubouti Y, Hunsche E. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or nonselective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology (Oxford). 2006;45(7):903-910.
15. Rohekar G, Pope J. Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol. 2009;36(10):2178-2182.